Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study

被引:11
|
作者
Filoni, A. [1 ,2 ]
Cicco, G. [1 ]
Lospalluti, L. [1 ]
Maglietta, A. [3 ]
Foti, C. [1 ]
Annichiarico, G. [4 ]
Resta, L. [3 ]
Bonamonte, D. [1 ]
机构
[1] Univ Bari, Sect Dermatol, Dept Biomed Sci & Human Oncol, Bari, Italy
[2] San Gallicano Dermatol Inst IRCCS, Rome, Italy
[3] Univ Bari, Dept Emergency & Organ Transplantat, Sect Pathol, Bari, Italy
[4] AReS Puglia, Reg Coordinat Rare Dis, Bari, Italy
关键词
GROWTH-FACTOR; FORMS; RISK;
D O I
10.1111/jdv.16022
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Recessive dystrophic epidermolysis bullosa is a highly disabling genodermatosis characterized by skin and mucosal fragility and blistering. Cutaneous squamous cell carcinoma (cSCC) is one of the most devastating complications, having a high morbidity and mortality rate. Patients with recessive dystrophic epidermolysis bullosa were reported to have up to a 70-fold higher risk of developing cSCC than unaffected individuals. Immune cells play a role in cancer evolution. Objective The aim of our study was to evaluate immunohistological differences between cSCC in patients with and without recessive dystrophic epidermolysis bullosa. Methods A retrospective study of 25 consecutive cases was performed; five were biopsies of cSCC taken from five patients with recessive dystrophic epidermolysis bullosa; as controls we analysed 10 cSCC in subjects without recessive dystrophic epidermolysis bullosa (5 primitive, 3 postburns and 2 postradiotherapy), 5 cSCC in renal transplant recipients and 5 cutaneous pseudoepitheliomatous hyperplasia in patients with recessive dystrophic epidermolysis bullosa. Results A significant reduction of CD3+, CD4+ and CD68+ between the cSCC in patients with recessive dystrophic epidermolysis bullosa compared to primary cSCC and a significant reduction of CD3+, CD4+, CD8+ and CD20+ were observed in cSCC in patients with recessive dystrophic epidermolysis bullosa compared to secondary cSCC. On the contrary, there was no difference in CD3+, CD8+, CD20+ and CD68+ expression when comparing cSCC in patients with recessive dystrophic epidermolysis bullosa to cSCC in renal transplant recipients. No significant difference was found in size, histopathology, grading, number of mitoses and EGFR expression between the different groups. Conclusions Our data show a reduction in immune cell peritumoral infiltration. Considering the well-known evolution of cSCC in patients with recessive dystrophic epidermolysis bullosa, as well as the younger age at diagnosis, it can be assumed that immune dysfunction might contribute to the cSCC aggressiveness in these patients.
引用
收藏
页码:1707 / 1714
页数:8
相关论文
共 50 条
  • [1] MORPHOLOGICAL AND MORPHOMETRICAL ANALYSIS OF CUTANEOUS SQUAMOUS CELL CARCINOMA IN PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: A PROSPECTIVE STUDY
    Filoni, Angela
    Lospalluti, Lucia
    Cicco, Gerolamo
    Maglietta, Antonella
    Annichiarico, Giuseppina
    Resta, Leonardo
    Bonamonte, Domenico
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 56 - 56
  • [2] Recessive dystrophic epidermolysis bullosa with squamous cell carcinoma
    Kim, M. H.
    Murrell, D. F.
    Intong, L. R. A.
    Kho, Y. C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB84 - AB84
  • [3] Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa
    Santucci, Catherine
    Alexandru, Madalina
    Chen, Xinyi
    Mellerio, Jemima E.
    Karagiannis, Sophia N.
    Jackow-Malinowska, Joanna
    HUMAN IMMUNOLOGY, 2024, 85 (03)
  • [4] Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study
    Filoni, Angela
    Cicco, Gerolamo
    Cazzato, Gerardo
    Bosco, Anna
    Lospalluti, Lucia
    Tucci, Marco
    Cimmino, Antonietta
    Foti, Caterina
    Marzullo, Andrea
    Bonamonte, Domenico
    LIFE-BASEL, 2022, 12 (02):
  • [5] Drug repurposing for treatment of recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma
    Pritchard, John
    Dayal, Jasbani
    Schoenherr, Christina
    Raponi, Michela
    Anand, Jayanthi
    Mcgarry, Lynn
    Corbyn, Ryan
    Carlin, Leo
    Blyth, Karen
    Inman, Gareth
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (06) : e96 - e97
  • [6] Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa
    Rami, Avina
    Laczmanski, Lukasz
    Jackow-Nowicka, Jagoda
    Jackow, Joanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (01) : 1 - 14
  • [7] Mechanisms of squamous cell carcinoma development in patients with recessive dystrophic epidermolysis bullosa
    Pickett-Leonard, M. D.
    Twaroski, K.
    South, A. P.
    Tolar, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S38 - S38
  • [8] SQUAMOUS-CELL CARCINOMA AND RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA
    FOUREL, E
    CLAUDY, AL
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1992, 119 (08): : 563 - 565
  • [9] Understanding the Pathogenesis of Recessive Dystrophic Epidermolysis Bullosa Squamous Cell Carcinoma
    South, Andrew P.
    O'Toole, Edel A.
    DERMATOLOGIC CLINICS, 2010, 28 (01) : 171 - +
  • [10] RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA COMPLICATED BY SQUAMOUS-CELL CARCINOMA
    TIDMAN, MJ
    MACDONALD, DM
    WELLS, RS
    BRITISH JOURNAL OF DERMATOLOGY, 1985, 113 : 82 - 82